Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans

Neuropsychopharmacology

Volumn 20, Issue 2, 1999, Pages 177-187

  Dépôt, Michelle ^a   Caillé, Gilles ^a   Mukherjee, Jayanti ^b   Katzman, Martin A ^c   Cadieux, Alain ^d   Bradwejn, Jacques ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

ACTH; Cholecystokinin tetrapeptide (CCK 4); Cortisol; Growth hormone; Neuropeptide Y; Ondansetron; Panic disorder; Prolactin

Indexed keywords

ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TETRAGASTRIN;

ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM;

EID: 0033081235     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00074-8     Document Type: Article

References (31)

1. Akiyoshi J., Isogawa K., Tsutsumi T., Kasturagi S., Kohno K., Furuta M., Yamamoto H., Yamada K., Fujii I. Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia. Biol Psychiatr. 42:1997;151-154.
2. Bradwejn J., Koszycki D. Imipramine antagonizes the panicogenic effects of CCK-4 in panic disorder patients. Am J Psychiatr. 151:1994;261-263. a.
3. Bradwejn J., Koszycki D., Couëtoux du Tertre A, Paradis M, Bourin M Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology. 114:1994;257-261. b.
4. Bradwejn J., Koszycki D., Meterissian G. Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatr. 35:1990;83-85.
5. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J., Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatr. 38:1995;742-746.
6. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatr. 48:1991;603-607.
7. 3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol. 164:1989;515-519.
8. Charney D.S., Woods S.W., Goodman W.K., Rifkin B., Kinch M., Aiken B., Quadrino L.M., Heininger G.R. Drug treatment of panic disorder. the comparative efficacy of imipramine, alprazolam, and trazodone J Clin Psychiatr. 47:1986;580-586.
9. 3) antagonist, GR 38032F, on midbrain dopamine (DA) neurons. Soc Neurosci 13:847 (Abstract 339.13).
10. Costall B., Domeney A.M., Gerrard P.A., Kelly M.E., Naylor R.J. Zacopride. An anxiolytic profile in rodent and primate models of anxiety J Pharm Pharmacol. 40:1988;302-305.
11. den Boer J.A., Westenberg H.G.M. Serotonin function in panic disorder. A double-blind placebo controlled study with fluvoxamine and ritanserin Psychopharmacology. 102:1990;85-94.
12. Guy J., Pelletier G., Bosler O. Serotonin innervation of neuropeptide Y-containing neurons in the rat arcuate nucleus. Neurosci Lett. 85:1988;9-13.
13. Heilig M., Wahlestedt C., Ekman R., Widerlov E. Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur J Pharmacol. 147:1988;465-467. a.
14. Heilig M., Wahlestedt C., Widerlov E. Neuropeptide Y (NPY)-induced suppression of activity in the rat. Evidence of NPY receptor heterogeneity and for interaction with α-adrenoceptors Eur J Pharmacol. 147:1988;205-213. b.
15. Itoh S., Takashima A., Katsuura G. Effect of cholecystokinin tetrapeptide amide on the metabolism of 5-hydroxytryptamine in the rat brain. Neuropharmacology. 27:1988;427-431.
16. 3 receptor antagonist. Br J Pharmacol. 93:1988;985-993.
17. Kendrick K., Leng G., Higuchi T. Noradrenaline, dopamine, and serotonin release in the paraventricular and supraoptic nuclei of the rat in response to intravenous cholecystokinin injections. J Neuroendocrinol. 3:1991;139-144.
18. Klein D.F. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiart. 50:1993;306-317.
19. Koszycki D., Zacharko R.M., Le Melledo J.M., Young S.N., Bradwejn J. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry. 40:1996;648-655.
20. 2 receptors by cholecystokinin receptor subtypes in rat neostriatal membranes. Brain Res. 650:1994;289-298.
21. Milgram S.L., McDonald J.K., Noe B.D. Interactions between norepinephrine and neuropeptide Y in regulating pancreatic islet hormone secretion. Ann NY Acad Sci. 611:1990;518-521.
22. Mouri T., Sone M., Takahashi K., Itoi K., Totsune K., Hayashi Y., Hasegawa S., Ohneda M., Murakami O., Miura Y., Katakura R., Tachibana S., Macbashi M. Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma, and neuroblastoma. Clin Sci. 83:1992;205-211.
23. 3 receptors in rat cerebral cortex and nucleus accumbens. Br J Pharmacol. 103:1991;1790-1794.
24. Pohl R., Balon R., Yeragani V.K., Gershon S. Serotonergic anxiolytics in the treatment of panic disorder. A controlled study with buspirone Psychopathology. 22:1989;60-67.
25. 3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats. Naunyn-Schmiedebergs Arch Pharmacol. 347:1993;111-114.
26. Rex A., Fink H., Marsden C.A. Effects of BOC-CCK-4 and L 365,260 on cortical 5-HT release in guinea pigs on exposure to the elevated plus maze. Neuropharmacology. 33:1994;559-565.
27. Schlicker E., Gross G., Fink K., Glaser T., Gothert M. Serotonin release in the rat brain cortex is inhibited by neuropeptide Y but not affected by ACTH 1-24, angiotensin II, bradykinin, and delta-sleep-inducing peptide. Naunyn-Schmiedebergs Arch Pharmacol. 343:1991;117-122.
28. Schneier F.R., Garfinkel R., Kennedy B., Campeas R., Fallon B., Marshall R., O'Donnell L., Hogan T., Lieboritz M.R. Ondansetron in the treatment of panic disorder. Anxiety. 2:1996;199-202.
29. Shlik J., Aluoja A., Vasar V., Vasar E., Podar T., Bradwejn J. Effects of citalopram treatment on behavioral, cardiovascular, and neuroendocrine response to cholecystokinin tetrapeptide in panic disorder patients. J Psychiatr Neurosci. 22:1997;332-340.
30. Van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A., Slaap B., Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology. 129:1997;357-364.
31. 3 receptors, antagonizes the antiexploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology. 110:1993;213-218.